Achillion Pharmaceuticals Inc (NASDAQ:ACHN)

3.63
Delayed Data
As of Oct 11
 +0.04 / +1.11%
Today’s Change
1.29
Today|||52-Week Range
5.03
+128.30%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$507.1M

Company Description

Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

Contact Information

Achillion Pharmaceuticals, Inc.
VEVA Building 14
Blue Bell Pennsylvania 19422
P:(215) 709-3040
Investor Relations:

Employees

Shareholders

Other institutional49.46%
Individual stakeholders38.13%
Mutual fund holders29.47%

Top Executives

Joseph TruittPresident, Chief Executive Officer & Director
Paul FirutaChief Operating Officer & Executive Vice President
Brian R. DiDonatoChief Financial Officer & Senior Vice President
Steven L. ZelenkofskeChief Medical Officer & Executive Vice President
Kevin P. MalobiskySVP-Global Regulatory Affairs & Compliance